このエントリーをはてなブックマークに追加
ID 56936
JaLCDOI
FullText URL
Thumnail 73_4_341.pdf 3.89 MB
Author
Kitajima, Kazuhiro Department of Radiology, Division of Nuclear Medicine and PET Center, Hyogo College of Medicine
Yamamoto, Shingo Department of Urology, Hyogo College of Medicine
Nakanishi, Yukako Department of Urology, Hyogo College of Medicine
Yamada, Yusuke Department of Urology, Hyogo College of Medicine
Hashimoto, Takahiko Department of Urology, Hyogo College of Medicine
Suzuki, Toru Department of Urology, Hyogo College of Medicine
Go, Shuken Department of Urology, Hyogo College of Medicine
Kanematsu, Akihiro Department of Urology, Hyogo College of Medicine
Nojima, Michio Department of Urology, Hyogo College of Medicine
Fujiwara, Masayuki Department of Radiology, Hyogo College of Medicine
Kaida, Hayato Department of Radiology, Kindai University Faculty of Medicine
Tsurusaki, Masakatsu Department of Radiology, Kindai University Faculty of Medicine
Kanda, Tomonori Department of Radiology, Kobe University Graduate School of Medicine
Tamaki, Yukihisa Department of Radiation Oncology, Shimane University School of Medicine
Yamakado, Koichiro Department of Radiology, Hyogo College of Medicine
Abstract
We investigated the effectiveness of 11C-choline-positron emission tomography/computed tomography (PET/CT) for evaluating treatment response in patients with prostate cancer or renal cell carcinoma. We performed 34 11C-choline PET/CT scans before/after a combined total of 17 courses of treatment in 6 patients with prostate cancer and 2 with renal cell carcinoma. The 17 treatments including hormonal therapy, radiotherapy, chemotherapy, radium-223, molecular target therapy, radiofrequency ablation, transcatheter arterial embolization, and cancer immunotherapy yielded 1 (5.9%) complete metabolic response (CMR), 3 (17.6%) partial metabolic responses (PMRs), 2 (11.8%) stable metabolic diseases (SMDs), and 11 (64.7%) progressive metabolic diseases (PMDs). Target lesions were observed in bone (n=14), lymph nodes (n=5), lung (n=2), prostate (n=2), and pleura (n=1), with CMR in 4, PMR in 10, SMD in 8 and PMD in 2 lesions. SUVmax values of the target lesions before and after treatment were 7.87±2.67 and 5.29±3.98, respectively, for a mean reduction of −35.4±43.6%. The response for the 8 prostate cancer-treatment courses was PMD, which correlated well with changes in serum prostatic specific antigen (PSA) (7 of 8 cases showed increased PSA). 11C-choline-PET/CT may be an effective tool for detecting viable residual tumors and evaluating treatment response in prostate cancer and renal cell carcinoma patients.
Keywords
treatment response
11C-choline PET/CT
prostate cancer
renal cell carcinoma
Amo Type
Original Article
Published Date
2019-08
Publication Title
Acta Medica Okayama
Volume
volume73
Issue
issue4
Publisher
Okayama University Medical School
Start Page
341
End Page
347
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
Copyright Holders
CopyrightⒸ 2019 by Okayama University Medical School
File Version
publisher
Refereed
True
PubMed ID